One should be cautious extrapolating from our mouse SKO model of CGL2 to partial lipodystrophy
According to primary trials in T2DM, tirzepatide significantly reduces clinical outcomes like body weight, glycated hemoglobin (HbA1c), lipid profiles, and glucose-adjusted glucagon secretion compared to typical glucagon-like peptide1 receptor agonists (GLP1RAs) [1, 2]
documentation availability and measured values are stated on the page for the lot they describe
from getting their prescriptions filled
Even more ambitious approaches are on the horizon
This inevitably bleeds into how we devise human reputation systems, caring more about something based on who you know and trust, and experiential offline activities with more curated groups of friends